1. Addressing the Challenges in Primary and Secondary Stroke Prevention

3. Program Goals

4. AF Epidemiology[a]

5. AF-Related Stroke

6. Warfarin for Stroke Prevention in AF

7. NOAC SPAF Trials Meta-Analysis of 71,683 Patients

8. Antithrombotic Treatment by Stroke Risk: GLORIA-AF Registry

9. Modifiable Risk Factors for Bleeding in Patients With AF

10. 2016 ESC Guidelines Stroke Prevention in AF

11. NOACs Reduce the Risk of ICH

12. Screening for AF

13. NOAC Trials for Stroke Prevention in AF: Baseline Characteristics

14. Nonadherence in AF

15. NOACs Reduce the Risk of All-Cause Mortality

16. Drug-Drug Interactions With NOACs

17. Anticoagulation After an ICH

18. NOAC Reversal Agents

19. Take-Home Messages

20. Abbreviations

21. Abbreviations (cont)